Clinical Trial: Efficacy and Safety of Second-Line Helicobacter Pylori Eradication

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07855497) titled 'Efficacy and Safety of Second-Line Helicobacter Pylori Eradication' on Sept. 28.

Brief Summary: Subjects with persistent H. pylori infection after first-line treatment failure receives either a 14-day PPI-based moxifloxacin triple regimen (esomeprazole, amoxicillin, and moxifloxacin) or a 14-day P-CAB-bismuth-containing moxifloxacin quadruple regimen (tegoprazan, amoxicillin, moxifloxacin, and bismuth).

Study Start Date: Feb. 01, 2021

Study Type: INTERVENTIONAL

Condition: HELICOBACTER PYLORI INFECTIONS

Intervention: DRUG: P-CAB-BM quadruple regimen

Esomeprazole, amoxicillin, and moxifloxacin

DRUG: Moxifloxacin triple regimen...